naltrexone low dose (STAT-205) / Statera BioPharma, Biostax Corp - LARVOL DELTA

Single-Blind Study of STAT-205 in Mild COVID-19 (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: Cytocom, Inc.; Not yet recruiting ➔ Recruiting; Phase classification: P2 ➔ P1; N=75 ➔ 24; Trial completion date: Apr 2022 ➔ Sep 2022; Initiation date: Apr 2021 ➔ Dec 2021; Trial primary completion date: Apr 2022 ➔ Jun 2022

Biomarker • Clinical • Enrollment change • Enrollment open • Phase classification • Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • CD4